David Jacoby
David Jacoby is an experienced development physician-scientist with a strong background in leading pipeline/portfolio advancement and early clinical development in various genetic indications such as neurodevelopmental disorders, cardiomyopathies, and metabolic diseases.
He has a successful track record that includes registering Brineura for the CLN2 form of Battens disease and Palynziq for PKU. David has also led the translation of AAV gene therapy for hemophilia A and biologicals for MPS 3B into clinical trials.
His expertise lies in developing biologics, gene therapy, antisense oligonucleotides, and small molecules for single gene disorders in neurology, hematology, metabolic, and pediatric disorders. He has managed programs from early stages through proof of concept, pivotal studies, and submission/approval.
David's specialties include neurology, rare/orphan diseases, molecular and clinical genetics, movement disorders, dystonia, bipolar depression, abdominal imaging, regulatory submissions, clinical development plans, publications, and IND-NDA submissions.
Education-wise, he pursued a B.A. in Biology at Swarthmore College and later completed an MD, PhD in Molecular Biology at the University of Pennsylvania School of Medicine.
His professional journey includes roles as Vice President Discovery Medicine, VP of Clinical Sciences, Executive Group Director of Clinical Sciences, and Senior Medical Group Leader in Neuroscience at BioMarin Pharmaceutical Inc. He also held positions as Head of Clinical Development at Repligen Corporation, Medical Director at Serono, Inc., and Associate Neurologist at Massachusetts General Hospital, among others.
David's experience spans various areas from independent consulting to leading medical and research initiatives at prestigious institutions like Massachusetts General Hospital and The Scripps Research Institute.
